Director/PDMR Shareholding

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Luke Miels

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

756

£17.3550

379

£17.3550

278

d)

Aggregated information

Aggregated volume Price

1,413

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

607

£17.3550

707

£17.3550

549

d)

Aggregated information

Aggregated volume Price

1,863

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

406

£17.3550

246

£17.3550

131

d)

Aggregated information

Aggregated volume Price

783

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Shobie Ramakrishnan

b)

Position/status

Chief Digital and Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Increase in notional interest in ADS following the re-investment of dividends paid to shareholders on 8 October 2026 on ADS held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5400

188

$46.5400

113

$46.5400

63

d)

Aggregated information

Aggregated volume Price

364

$46.5400

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

David Redfern

b)

Position/status

President, Corporate Development

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

481

£17.3550

219

£17.3550

194

d)

Aggregated information

Aggregated volume Price

894

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Regis Simard

b)

Position/status

President, Global Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

579

£17.3550

321

£17.3550

203

d)

Aggregated information

Aggregated volume Price

1,103

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Philip Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

324

£17.3550

195

£17.3550

141

d)

Aggregated information

Aggregated volume Price

660

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Deborah Waterhouse

b)

Position/status

CEO, ViiV Healthcare and President, Global Health, GSK

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

501

£17.3550

302

£17.3550

184

d)

Aggregated information

Aggregated volume Price

987

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Tony Wood

b)

Position/status

Chief Scientific Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Deferred Annual Bonus Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£17.3550

618

£17.3550

281

£17.3550

258

d)

Aggregated information

Aggregated volume Price

1,157

£17.3550

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Maya Martinez-Davis

b)

Position/status

President, US

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADS')

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADS following the re-investment of dividends paid to shareholders on 8 October 2026

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$46.5400

179.308

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Details of PDMR/person closely associated with them (‘PCA’)

a)

Name

Julie Brown

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each (‘Ordinary Shares’)

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 8 October 2026 on Ordinary Shares held in the Company’s Performance Share Plan subject to a 2-year holding period

c)

Price(s) and volume(s)

d)

Aggregated information

Aggregated volume Price

N/A (single transaction)

e)

Date of the transaction

2026-10-12

f)

Place of the transaction

London Stock Exchange (XLON)